30 results
Thumbnail

- D1.524 - StingReady: a safe and alternative method for controlled sting challenge tests

Thumbnail

- D1.515 - Occupational Exposure of Patients Allergic to Hymenoptera Venom

Thumbnail

- D1.516 - Compliance with hymenoptera venom inmunotherapy (VIT)

Thumbnail

- D1.517 - Adverse Reactions to Insect Venom Immunotherapy in a Reference Center

Thumbnail

- D1.518 - Patient Phenotypes in Prolonged Immunotherapy for Hymenoptera Venom

Thumbnail

- D1.519 - Safety of ultra-rush protocols in venom immunotherapy: a systematic review and meta-analysis of Portuguese data

Thumbnail

- D1.520 - Immunological modulation during Apis mellifera venom immunotherapy

Thumbnail

- D1.521 - Rarer occurrence of cancer and autoimmune diseases among older patients with life-threatening allergic reactions to insect venom

Thumbnail

- D1.522 - Efficacy of hymenoptera venom immunotherapy in Portugal: a systematic review

Thumbnail

- D1.523 - Clinical characterization of patients with Hymenoptera venom allergy undergoing venom immunotherapy stratified by basal serum tryptase

Thumbnail

- D1.525 - Implementation of allergen-specific immunotherapy for insect allergy

Thumbnail

D1.526 - Epidemiologic Characteristics of Hymenoptera Venom Allergic Patients from Two Different Environmental Areas

Thumbnail

- D1.527 - Low tryptase and combined IgE biomarkers have limited predictive value in children with severe honeybee venom anaphylaxis

Thumbnail

D3.418 - A Phase 1b Study of Lesigercept, a Long-acting High-affinity IgETrap-Fc Fusion Protein: Safety, Tolerability, PK, and PD in Atopic Healthy and Allergic Subjects

Thumbnail

D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset

Thumbnail

D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study

Thumbnail

D3.421 - Real-world Effectiveness and Safety of Lanadelumab Treatment in Patients With Hereditary Angioedema: The 12-Month Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)

Thumbnail

D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes

Thumbnail

D3.423 - Lanadelumab treatment is effective and safe in patients with Factor XII associated cold-induced autoinflammatory syndrome: results from an open-label proof-of-concept study

Thumbnail

D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria